Key Takeaways SOLV posted a strong Q2 FY25 with 2.8% organic growth and raised full-year revenue guidance.SOLV's growth is driven by improved commercial focus and product innovation in MedSurg, Dental, and HIS.Tariff risks loom, but SOLV's strategic mitigations support sustained profitability.Solventum Corporation (SOLV) delivered a robust second-quarter performance, reflecting the company’s progress on its multi-phase transformation and renewed commercial focus. SOLV reported earnings per share (EPS) of $1 ...